The Motley Fool··Prosper Junior BakinyGLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race
Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share